complete primary vaccine series in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Arbel, 2021 (REV) 10.00 [7.07; 14.14]
Barda, 2021 (REV) 5.26 [1.42; 19.46]
McConeghy, 2022 (REV) 33.33 [9.62; 115.47]
11.58 [5.18 ; 25.87 ] Arbel, 2021 (REV), Barda, 2021 (REV), McConeghy, 2022 (REV) 3 55% 843,208 moderate not evaluable hospitalization or deathdetailed results Abu-Raddad, 2022 (REV) 4.35 [2.27; 8.33]
McConeghy, 2022 (REV) 5.56 [2.03; 15.21]
4.67 [2.71 ; 8.07 ] Abu-Raddad, 2022 (REV), McConeghy, 2022 (REV) 2 0% NA not evaluable confirmed COVID (any severity)detailed results Abu-Raddad, 2022 (REV) 1.96 [1.87; 2.06]
Bar-On, 2021 (REV) 11.36 [10.04; 12.87]
C4591031- first boost, 2021 (REV) 18.52 [7.91; 43.34]
COVI3, 2022 (REV) 14.29 [4.52; 45.18]
Kislaya, 2022 (REV) 3.23 [1.86; 5.59]
Mattiuzzi, 2022 (REV) 2.86 [2.62; 3.11]
McConeghy, 2022 (REV) 2.04 [1.43; 2.91]
Patalon, 2021 (REV) 4.76 [3.60; 6.30]
Patalon, 2022 (REV) 6.67 [6.05; 7.35]
4.98 [2.97 ; 8.34 ] Abu-Raddad, 2022 (REV), Bar-On, 2021 (REV), C4591031- first boost, 2021 (REV), COVI3, 2022 (REV), Kislaya, 2022 (REV), Mattiuzzi, 2022 (REV), McConeghy, 2022 (REV), Patalon, 2021 (REV), Patalon, 2022 (REV) 9 99% 10,125 NA not evaluable hospitalizationdetailed results Barda, 2021 (REV) 14.29 [7.14; 28.57]
Lauring, 2022 (REV) 16.67 [13.18; 21.08]
Mattiuzzi, 2022 (REV) 3.23 [2.28; 4.56]
McConeghy, 2022 (REV) 1.92 [0.28; 13.28]
Patalon, 2022 (REV) 12.50 [7.75; 20.16]
Tenforde, 2022 (REV) 5.49 [2.82; 10.68]
7.74 [3.74 ; 16.05 ] Barda, 2021 (REV), Lauring, 2022 (REV), Mattiuzzi, 2022 (REV), McConeghy, 2022 (REV), Patalon, 2022 (REV), Tenforde, 2022 (REV) 6 93% 398,920 NA not evaluable symptomatic Covid-19detailed results Abu-Raddad, 2022 (REV) 1.96 [1.87; 2.06]
COVI3, 2022 (REV) 14.29 [4.04; 50.51]
4.77 [0.69 ; 33.03 ] Abu-Raddad, 2022 (REV), COVI3, 2022 (REV) 2 89% NA not evaluable ICU admissiondetailed results Mattiuzzi, 2022 (REV) 3.03 [0.74; 12.45]
3.03 [0.74 ; 12.45 ] Mattiuzzi, 2022 (REV) 1 0% NA not evaluable severe COVID-19 (FDA definition)detailed results C4591031- first boost, 2021 (REV) 4.03 [0.18; 89.41]
4.03 [0.18 ; 89.41 ] C4591031- first boost, 2021 (REV) 1 0% 10,125 NA not evaluable severe COVID-19 occurrencedetailed results Bar-On, 2021 (REV) 15.38 [10.47; 22.61]
Barda, 2021 (REV) 12.50 [5.10; 30.62]
C4591031- first boost, 2021 (REV) 4.03 [0.18; 89.41]
14.65 [10.31 ; 20.81 ] Bar-On, 2021 (REV), Barda, 2021 (REV), C4591031- first boost, 2021 (REV) 3 0% 10,125 NA not evaluable arrhythmiadetailed results C4591031- first boost, 2021 (REV) 0.50 [0.02; 15.01]
0.50 [0.02 ; 15.01 ] C4591031- first boost, 2021 (REV) 1 0% 10,075 NA not evaluable hypertensiondetailed results C4591031- first boost, 2021 (REV) 2.01 [0.07; 60.05]
2.01 [0.07 ; 60.05 ] C4591031- first boost, 2021 (REV) 1 0% 10,075 NA not evaluable Myocardial infarction detailed results C4591031- first boost, 2021 (REV) 1.34 [0.30; 6.00]
1.34 [0.30 ; 6.00 ] C4591031- first boost, 2021 (REV) 1 0% 10,075 NA not evaluable pulmonary embolismdetailed results C4591031- first boost, 2021 (REV) 6.04 [0.30; 120.71]
6.04 [0.30 ; 120.71 ] C4591031- first boost, 2021 (REV) 1 0% 10,075 NA not evaluable stroke (non-specific, hemorrhagic, and ischemic)detailed results C4591031- first boost, 2021 (REV) 1.01 [0.06; 16.10]
1.01 [0.06 ; 16.10 ] C4591031- first boost, 2021 (REV) 1 0% 10,075 NA not evaluable cerebral venous sinus thrombosis (CVST)detailed results C4591031- first boost, 2021 (REV) 2.01 [0.07; 60.05]
2.01 [0.07 ; 60.05 ] C4591031- first boost, 2021 (REV) 1 0% 10,075 NA not evaluable appendicitisdetailed results C4591031- first boost, 2021 (REV) 0.25 [0.01; 5.58]
0.25 [0.01 ; 5.58 ] C4591031- first boost, 2021 (REV) 1 0% 10,075 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-09 23:21 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
